


Your dedicated *research* analyst.



01 THESIS

The hard part isn't the *AI*.

An LLM can summarize, reason, and write — it can search the web. What it still can't do, an analyst can. And that's the problem we solve.

01

Know what's true

Web search returns press releases and outdated articles. A curated, cross-referenced database of **593,000 drug programs** returns signal.

02

Cross-reference

MK-3475, pembrolizumab, and Keytruda are the same molecule. Identity resolution across **56 identifier systems** makes it obvious.

03

Query at scale

An LLM looks up one drug at a time. We run structured queries across **41M molecules**, **308M patent links**, and **577k trials**.

04

Show its work

Every answer traces back to a primary source — a specific database record, a specific trial ID, a specific patent family. No hand-waving.

The AI is the interface.
The value is in the *infrastructure underneath*.

02 WHAT WE MAINTAIN

A data layer, not a *search* engine.

We maintain the substrate — curated, cross-referenced, and refreshed. Ask a question in plain English; the system decides what to query.

DRUG PROGRAMS

593_K

Every publicly-disclosed program, with company, target, indication, phase, and regulatory status.

MOLECULES

41_M

Structures, properties, identifiers, parent/salt resolution — all reconciled into one record.

PATENT LINKS

308_M

Molecule-to-patent links with evidence tiers, expiry, jurisdiction, family.

CLINICAL TRIALS

577_K

The full ClinicalTrials.gov corpus, linked to molecules, targets, and sponsors.

25+ live APIs on top — *PubMed, OpenFDA, ChEMBL, AlphaFold, OpenTargets*. The system decides when to use them.

— 03 POSITIONING

We do *one thing*.
Make your analytical work
faster and sharper.

WHERE LUVIA FITS

- Due diligence on drug programs and biotech companies

- Competitive landscape and target-indication analysis

- Patent and IP exposure mapping

- Portfolio monitoring — live readouts, filtered to what you work on

WHAT LUVIA IS NOT

- We don't write analyst reports with editorial opinions

- We don't provide consensus revenue forecasts

- We don't replace Bloomberg, FactSet, or market data terminals

- We don't do portfolio accounting or risk management

04 WHO'S BUILDING THIS


A small team. Senior to the problem.



Elis Samskog

CO-FOUNDER

Industrial Management & Applied Mathematics, KTH. Financial mathematics. Previously Första AP-fonden — built risk framework for systemic FDA events, adopted internally.



David Fornander

CO-FOUNDER

Computer Science & Engineering, KTH. Designed AI systems for Edaider's 30,000+ paying customers and a licence platform deployed across 100+ Swedish corporations & universities. Runs Luvia's infrastructure and security.



Benjamin Nordin

SENIOR ADVISOR

20+ years Nordic life - sciences finance. Equity research and corporate finance at Pareto Securities, Carnegie, ABG Sundal Collier. CBO at Key2Brain AB.

Luvia.

DIRECT

elis@luvia-systems.com

WEB

luvia-systems.com

LOCATION

Stockholm · Q2 2026